obesense - nano-tera 2016

8/17/2019 ObeSense - Nano-Tera 2016

1/21

ObeSenseMonitoring the Consequences of Obesity


2/21

Motivations

• Obesity is associated with multiple health problems

– Cardiovascular diseases

– Atrial fibrillation

– Hypertension

– Obstructive sleep apnea

– Diabetes

– Certain types of cancer

• Has been proven to reduce life epectancy !

– "#$ of premature adult deaths

• %s reaching epidemic proportions

– & ! Swit'erland ! ()*+$ overweight, )*-$ obese

– +*-$ of the total healthcare epenses

• .uidelines about identification, evaluation and treatment eist

– /hose guidelines require long0term monitoring

– Such monitoring systems do not eist

1


3/21

Ob2ectives

• Answer a clear medical need by 2oining research in

physiological mar3ers sensors with clinical end0users – Develop innovative and non0invasive sensors

– %ntegrate them into single long0term monitoring systems adapted

to obese patients4 Multi-parametric, low-power, allergy-free, comfortable, with on-line feedback.

– %nnovations in4 Sensors (including robustness & cost)

4 Algorithms (in real-life conditions)

4 ltra-low power !" & S" design

4 #ntegration into smart te$tiles

4 %linical practice – Central involvement of end0users

4 hrough ' clinical scenarios

-


4/21

Clinical scenarios

• Scenario "! physical activity 5 lifestyle

interventions – Supervised by Dr O* D6ria' 7%889 and Dr :* M;der 7S


5/21

/echnical developments 5 validations

• Sensors, systems and algorithms – 8espiratory rate and volume

4 ew optical fiber belt system (M*A)

– ?ater vapor permeable

– Ad2ustable in si'e

– is protected from eternal light

– @ have been delivered for validation

4 +edicated e$ploratory platform (%SM) – @ measurement channels

– %solated DCDC converter, certified for medical application 7%&C

@#@#"0"9

– :SB battery recharger

– Approved by Swissmedic

4


6/21


• Sensors, systems and algorithms

– 8espiratory rate and volume4 ew optical fiber belt system (M*A)

– ?ater vapor permeable

– Ad2ustable in si'e

– is protected from eternal light

– @ have been delivered for validation

4 +edicated e$ploratory platform (%SM)

– @ measurement channels

– %solated DCDC converter, certified for medical application 7%&C @#@#"0"9

– :SB battery recharger

– Approved by Swissmedic

4 alidation

4

@


7/21



– Cardiac Output

4 # (*-S/ & %SM) 0 – Better understanding of the origin of the &%/ signal

– -D dynamic bio0impedance model from M8 data

– Confirmation of the feasibility of estimating stro3e volume 7S>9 by &%/ – &vidence of the sensitivity to electrode displacement

– Optimi'ation of the &%/ measurement setup

– Clinical validation in preparation

4 7Swissethics %D! 1#"0##1#-9

4 Systolic olume 1alance (*-!%) –

Cardiac output estimation by processing of pressurewaveforms

– Comparison with commercial systems 7efin9

+


8/21



– 8espiratory rate and volume – Cardiac Output

– &nergy ependiture 7CS&M, :SE, %88, &=


9/21






10/21






11/21






12/21




– &nergy ependiture 7CS&M, :SE, %88, &=erified on healthy volunteers

– >alidation protocol with the CH:>

– Safety and conformity test passed

– Swissmedic approval for a clinical study obtained in Oct 1#"

– &thical Committee approval in December 1#"

– On0going clinical trial 7CH:> 5 %nselspital9

"1


13/21


14/21



– Cardiac Output



15/21



– Cardiac Output



16/21



– Cardiac Output



17/21

Clinical scenarios

• Scenario "! physical activity 5 lifestyle

interventions

– Supervised by Dr O* D6ria' 7%889 and Dr :* M;der

7S


18/21

=latform development versus clinical scenarios ")


19/21

Scenario % ! =hysical activity monitoring "G

• =latform ?&S 7activity trac3er9 – >alidation of physiological parameters with

scientific publications 7M&/ model, wal3ing

and running speed and distance9

– >alidation of &C. quality sufficient for

diagnosis 7on going 0 to be published9

– C& mar3ing with medical safety standards

– Compatible with off0the0shelf smart tetiles

7=olar, Addidas, >ictoriaKs secret, etc*9

– 8eady for industrial transfer


20/21

Scenario %% ! Blood pressure monitoring 1#

• =latform B= 7dedicated multi0

sensors9 – /arget medical C& mar3ing

– Approved Swissmedic 5 &thics committee

– >alidation of estimated central blood pressure

against catheter measurements 7on0goingclinical trials at the CH:> and at the

%nselspital9

– 7Almost09ready for industrial transfer


21/21

Conclusions

• ObeSense contributed

– A series of methods and devices4 eading edge scientific research

4 *rototype integration

4 ocus on the 2alidation

4 Se2eral fully integrated, 2alidated and

certified

– Several on0going clinical validation

studies4 thical committee appro2ed

4 7n-going data collection and analysis

1"

obesense - nano-tera 2016

Documents